Evidence map›Paper›PMID 41448908›Full record

Observational studySexually transmitted infections2026

High prevalence and incidence of curable sexually transmitted infections among young women using oral HIV pre-exposure prophylaxis in sub-Saharan Africa: results from the INSIGHT Cohort study.

Irene Mukui, Sue Peacock, Deborah Donnell, Brenda Gati-Mirembe, Meighan Krows, Elizabeth A Bukusi, Loveness Imaan, Philip Kotze, Katherine Margaret Gill, Pippa Macdonald and 12 more

Registry-linked trialAbstract readMulticenter StudyObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Sexually transmitted infections, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05746065 (A Cohort for Evaluation of Open-label PrEP Delivery and PrEP Preferences Among African Women), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05746065 completednot on this map

A Cohort for Evaluation of Open-label PrEP Delivery and PrEP Preferences Among African Women

TypeobservationalSponsorUniversity of WashingtonRan2022 to 2023Enrolled3,087ConditionsHIV InfectionsArmsPrEP
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Irene MukuiDepartment of Global Health, University of Washington, Seattle, Washington, USA.ORCID http://orcid.org/0000-0002-3699-1841
Sue PeacockDepartment of Global Health, University of Washington, Seattle, Washington, USA.
Deborah DonnellDepartment of Global Health, University of Washington, Seattle, Washington, USA.
Brenda Gati-MirembeMakerere University-Johns Hopkins University Research Collaboration, Kampala, Central Region, Uganda.
Meighan KrowsDepartment of Global Health, University of Washington, Seattle, Washington, USA.
Elizabeth A BukusiCenter for Microbiology Research, Kenya Medical Research Institute, Nairobi, Kenya.
Loveness ImaanJohns Hopkins Research Project-Kamuzu University of Health Sciences, Blantyre, Malawi.
Philip KotzeQhakaza Mbokodo Research Clinic, Ladysmith, South Africa.
Katherine Margaret GillDesmond Tutu HIV Centre, Institute of Infectious Disease and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, Western Cape, South Africa.ORCID http://orcid.org/0000-0002-3372-9506
Pippa MacdonaldDesmond Tutu HIV Centre, Institute of Infectious Disease and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, Western Cape, South Africa.
Cheryl LouwMadibeng Centre for Research, Brits, South Africa.
Manjeetha JaggernathWits Maternal Adolescent and Child Health Research, Durban, South Africa.
Anita MaraisPerinatal HIV Research Unit HIV Prevention Clinical Research Site, University of the Witwatersrand, Soweto, South Africa.
Remco P H PetersFoundation for Professional Development, Research Unit, East London, Pretoria, South Africa.
Sinead Delany-MoretlweWits RHI, University of the Witwatersrand, Hillbrow, Johannesburg, South Africa.ORCID http://orcid.org/0000-0003-0376-1019
Amy WardVuka Research Clinic, Department of Medicine, University of Cape Town, Cape Town, South Africa.
Phillip du PreezVuka Research Clinic, Department of Medicine, University of Cape Town, Cape Town, South Africa.
Margaret KasaroUniversity of North Carolina Global Projects Zambia, Lusaka, Zambia.
Monica GandhiDepartment of Medicine, University of California, San Francisco, San Francisco, California, USA.
Renee HeffronDepartment of Medicine, University of Alabama, Birmingham, Alabama, USA.
Connie CelumDepartment of Global Health, University of Washington, Seattle, Washington, USA ccelum@uw.edu.
INSIGHT Study Team

Funding

Bill & Melinda Gates Foundation INV-004743
6 · The paper itself

Abstract

backgroundHIV pre-exposure prophylaxis (PrEP) programmes in Africa reach young women at risk of sexually transmitted infections (STIs). We evaluated curable STI prevalence, incidence and risk factors among women initiating PrEP.

methodsFrom August to December 2022, sexually active women aged 16-30 years from 15 South African sites, and one site each in Eswatini, Kenya, Malawi, Uganda and Zambia were enrolled into the INSIGHT cohort and offered oral emtricitabine/tenofovir PrEP with follow-up at 1, 3 and 6 months. At each visit, STI symptoms were assessed and treatment provided based on syndromic management or diagnostic testing. Diagnostic tests included nucleic acid amplification for

resultsOf 3087 participants offered daily oral PrEP with a median age of 23 (IQR 21-27), 3011 had STI results and 30.9% had one or more STIs, with 15.7% reporting symptoms. The prevalence of

conclusionThe high prevalence and incidence of STIs among African women initiating PrEP, most of whom did not report symptoms, highlights the need for aetiologic testing to detect STIs, guide treatment and reduce reproductive health sequelae and risk of transmission. TRIAL REGISTRATION NUMBER: clinicaltrials.gov NCT05746065.

Indexed as

Anti-HIV AgentsHIV InfectionsPre-Exposure ProphylaxisSexually Transmitted DiseasesAdministration, OralAdolescentAdultAfrica South of the SaharaCohort StudiesFemaleHumansIncidencePrevalenceRisk FactorsSub-Saharan African PeopleSyphilisAnti-HIV AgentsAFRICAPre-Exposure ProphylaxisPrevalenceReproductive Tract InfectionsWOMEN

Identifiers

PMID41448908
PMCPMC13539827

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.